Synergistic effects of L5 and Aβ on GPIIb/IIIa activation and aggregation in human platelets. (A) Flow cytometry analysis of GPIIb/IIIa-activated platelets that were pretreated with vehicle (0.1% DMSO; first column), TS92 (10 μg/mL), BMS-345541 (25 μM), or Bay1170-82 (20 μM), before the addition of L1 (50 μg/mL), L5 (25 μg/mL), or Aβ (10 μM), followed by 2 μL of FITC-fibrinogen. Data are expressed as a ratio to the vehicle-treated control (Ctl) group. Data are expressed as the mean ± SD (n = 6); *P < .05, ***P < .001 vs vehicle-treated control; ###P < .001 vs L5+Aβ-treated group. P values were determined by using 1-way analysis of variance with the Bonferroni post hoc test. (B) Platelet aggregation was measured with a platelet aggregometer. Washed platelets (3.6 × 10⁸/mL) were treated with Aβ (10 μM) or L5 (25 μg/mL) and Aβ (10 μM). Platelets were preincubated with vehicle (0.1% DMSO), TS92 (10 μg/mL), BMS-345541 (25 μΜ), or Bay1170-82 (20 μM) before the addition of L5 and Aβ. Data are representative of 4 independent experiments with similar results.